Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRDS Pardes Biosciences (PRDS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Pardes Biosciences Stock (NASDAQ:PRDS) 30 days 90 days 365 days Advanced Chart Ad DTIEver heard of this 8-day bitcoin profit window? Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.It’s coming up quick. Get Pardes Biosciences alerts:Sign Up Key Stats Today's Range$2.16▼$2.1650-Day Range$2.13▼$2.1652-Week Range$0.75▼$3.93Volume400 shsAverage Volume359,530 shsMarket Capitalization$133.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.Read More… “This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Receive PRDS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pardes Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PRDS Stock News HeadlinesPardes Hanna, Israel - Weather Forecasts | Maps | News - Yahoo WeatherOctober 31, 2023 | yahoo.comPardes Biosciences Announces Closing of Tender OfferAugust 31, 2023 | finance.yahoo.com917 Trades… Zero Losses?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”November 22, 2024 | Insiders Exposed (Ad)MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesAugust 28, 2023 | finance.yahoo.comMediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesAugust 17, 2023 | finance.yahoo.comPardes Biosciences (PRDS) Price Target Decreased by 28.57% to 1.28August 3, 2023 | msn.comPardes Biosciences Shares Rise 15% After Buyout Offer From MediPacificJuly 19, 2023 | marketwatch.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pardes Bioscience, Inc. (PRDS)July 19, 2023 | markets.businessinsider.comSee More Headlines PRDS Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Pardes Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pardes Biosciences investors own include Meta Platforms (META), Valneva (VALN), Arcturus Therapeutics (ARCT), Apellis Pharmaceuticals (APLS), Annexon (ANNX), ANI Pharmaceuticals (ANIP) and AnaptysBio (ANAB). Company Calendar Today11/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:PRDS CUSIPN/A CIK1822711 Webwww.pardesbio.com Phone415-649-8758FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.36% Return on Assets-40.71% Debt Debt-to-Equity RatioN/A Current Ratio81.72 Quick Ratio81.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.51 per share Price / Book0.86Miscellaneous Outstanding Shares62,012,000Free Float36,711,000Market Cap$133.95 million OptionableNot Optionable Beta0.42 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:PRDS) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredBREAKING: NVDA loses $175 billion in 8 minutesIt's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, w...Chaikin Analytics | SponsoredThe AI Crash Begins November 30thMost AI stocks are doomed. I’m not an AI hater. AI will absolutely continue to be the most disruptive tech...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pardes Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pardes Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
